Slide 1: Delivering the Power of Sight
Delivering the Power of Sight Investor Presentation May 2023 ® ™
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act o
Slide 3: Our Mission: Eye Care Innovation in Glaucoma and Dry Eye
2 To transform the treatment of Glaucoma and Dry Eye through a broad portfolio of innovative solutions Our solutions are designed for earlier intervention and to help restore the natural functionality of healthy eyes Our Mission Eye Care Innovation in Glaucoma and Dry Eye
Slide 4: Current Product Portfolio and Market Opportunity
Current Product Portfolio and Market Opportunity Developing a comprehensive portfolio of POAG and DED treatment options 3.4M Diagnosed U.S. patients $6B U.S. TAM 14M Evaporative DED diagnosed U.S. patients $10B U.S. TAM >160K Cases performed3 >35K Cases performed3 OMNI® Surgical System is indicated
Slide 5: Strategic Value-Creation Initiatives
Strategic Value-Creation Initiatives Bedrock of Clinical Excellence: numerous completed, ongoing and planned trials in POAG and DED 4 Train New OMNI Surgeons Expand OMNI Usage in Standalone and Combination Cataract MIGS Procedures SURGICAL GLAUCOMA Extend Portfolio by introducing SION for certain cu
Slide 6: OMNI addresses all three primary points of resistance
We believe OMNI is singularly well-suited to address all three primary points of resistance Underlying POAG Diseased Anatomy TRABECULAR MESHWORK SCHLEMM’S CANAL COLLECTOR CHANNELS Trabecular Bypass Stents Canaloplasty Only Trabeculotomy Only 1 2 3 1 2 3 TRABECULAR MESHWORK SCHLEMM’S CANAL DISTAL COL
Slide 7: OMNI: Interventional POAG Procedure
6 OMNI: Interventional POAG Procedure Two sequential, ab interno MIGS procedures to help restore natural drainage in the eye Up to 360° coverage with a single clear corneal microincision Trabeculotomy using OMNI Canaloplasty using OMNI Schlemm’s Canal Schlemm’s Canal Trabecular Meshwork Trabecular M
Slide 8: Market Leading Label Allows Broad Use in POAG
Market Leading Label Allows Broad Use in POAG PRESCRIPTION MEDICATIONS STANDALONE (>85%1 of POAG; ~5.4M eyes) COMBINATION CATARACT (<15%1; ~0.8M eyes) CONVENTIONAL TREATMENTS TRABECULAR BYPASS STENTS LASER TRABECULOPLASTY CONVENTIONAL SURGERY MILD (~40%) MODERATE (~40%) ADVANCED (~20%) Represents in
Slide 9: OMNI: Customizable to All Six MIGS Categories in POAG
OMNI: Customizable to All Six MIGS Categories in POAG2 Low Risk of Hyphema Consistency of Efficacy Degree of Efficacy Represents internal analysis of third-party estimates for % of U.S. POAG TAM. The described procedures are presented for illustrative purposes only and are based on observed physicia
Slide 10: OMNI Clinical Roadmap
AAO IRIS® Registry PRECISION Database of over 483 million real-world visits by 78 million de-identified patients submitted by ophthalmologists Compares OMNI, iStent® and Hydrus® in combination with cataract surgery Two year IOP reduction and medication usage Plan to publish in peer-reviewed journal
Slide 11: SION: Bladeless Goniotomy Procedure
Complement to OMNI for Certain Customer Subsegments 10 Fully meets AAO definition of goniotomy, aligns with Category I CPT code 65820 Innovative design bladelessly excises diseased trabecular meshwork within several clock-hours SION: Bladeless Goniotomy Procedure
Slide 12: Large Market Opportunity in Evaporative Dry Eye / Meibomian Gland Disease
Large Market Opportunity in Evaporative Dry Eye / Meibomian Gland Disease MEIBOMIAN GLANDS MGD is present in 14 million diagnosed dry eye cases Growing prevalence: linked to many prominent demographic, medical and sociological trends Currently, Medicare and most commercial health plans do not cover
Slide 13: Our Solution: TearCare
Our Solution: TearCare The only wearable eyelid technology designed to melt and remove meibomian gland obstructions TearCare Technology Steady temperature and precise heat delivery Single-use SmartLids™ conform to variable eyelid anatomy while allowing natural blinking Designed for intuitive provide
Slide 14: The SAHARA RCT
The SAHARA RCT Note: Clinical trials, including their design, endpoints and timing, are subject to change at the Company’s discretion. Initial results may include preliminary data and interim analyses that are subject to change. 2021 First patient, first visit 2Q 2021 2022 Enrollment completed 3Q 20
Slide 15: Develop Comprehensive Best-in-Class Portfolio: Surgical Glaucoma Pipeline
Develop Comprehensive Best-in-Class Portfolio SURGICAL GLAUCOMA PIPELINE MILD TO MODERATE DISEASE In-office Injection of Sustained Release Pharmaceutical (Rx)* 1 MILD TO MODERATE DISEASE OR Performed Canal-based Glaucoma Surgery (MIGS) MODERATE TO ADVANCED DISEASE OR Performed Suprachoroidal Implant
Slide 16: Develop Comprehensive Best-in-Class Portfolio: Dry Eye Pipeline
Over-the-counter Artificial Tear With A Differentiated Lipid Layer Technology* Dry Eye Disease Prescription Pharmaceutical Eyelid Ointment* Office-Based Eyelid Procedure Home-Based Eyelid Device Treatment* 1 2 4 Develop Comprehensive Best-in-Class Portfolio DRY EYE PIPELINE 3 15 *This pipeline produ
Slide 17: Strong Financial Profile
Strong Financial Profile 25 Annual Revenue FY18-FY22 CAGR: +76% Quarterly Revenue Q1’23 Growth: +26% vs. Q1’22 FY22 Revenue: $71.3M, +46% Surgical Glaucoma: $65.6M, +41% Dry Eye: $5.7M, +133% ($ Millions) ($ Millions) $18.8 $14.9 $17.2 $18.7 $20.5 $7.5 $23.3 $27.6 $49.0 $71.3 16 Balance Sheet $167.3